Bai Yao, Peng Zhihang, Wei Fengying, Jin Zhen, Wang Jinjie, Xu Ximing, Zhang Xinyan, Xu Jun, Ren Zixiong, Lu Bulai, Wang Zhaojun, Xu Jianguo, Huang Senzhong
Xi'an Center for Disease Control and Prevention, Xi'an 710054, Shaanxi, China.
Institute of Public Health, Nankai University, Tianjin 300071, China.
J Biosaf Biosecur. 2023 Mar;5(1):39-44. doi: 10.1016/j.jobb.2023.03.001. Epub 2023 Mar 22.
The prediction system EpiSIX was used to study the COVID-19 epidemic in mainland China between November 2022 and January 2023, based on reported data from December 9, 2022, to January 30, 2023, released by The Chinese Center for Disease Control and Prevention on February 1, 2023. Three kinds of reported data were used for model fitting: the daily numbers of positive nucleic acid tests and deaths, and the daily number of hospital beds taken by COVID-19 patients. It was estimated that the overall infection rate was 87.54% and the overall case fatality rate was 0.078%-0.116% (median 0.100%). Assuming that a new COVID-19 epidemic outbreak would start in March or April of 2023, induced by a slightly more infectious mutant strain, we predicted a possible large rebound between September and October 2023, with a peak demand of between 800,000 and 900,000 inpatient beds. If no such new outbreak was induced by other variants, then the current COVID-19 epidemic course in mainland China would remain under control until the end of 2023. However, it is suggested that the necessary medical resources be prepared to manage possible COVID-19 epidemic emergencies in the near future, especially for the period between September and October 2023.
基于中国疾病预防控制中心于2023年2月1日发布的2022年12月9日至2023年1月30日的报告数据,预测系统EpiSIX被用于研究2022年11月至2023年1月中国大陆的新冠疫情。三种报告数据被用于模型拟合:每日核酸检测阳性数和死亡数,以及新冠患者占用的每日病床数。据估计,总体感染率为87.54%,总体病死率为0.078%-0.116%(中位数为0.100%)。假设2023年3月或4月由传染性稍强的突变株引发新冠疫情新的爆发,我们预测2023年9月至10月可能会出现大幅反弹,住院床位需求峰值在80万至90万之间。如果没有其他变异株引发此类新的疫情爆发,那么中国大陆目前的新冠疫情进程将在2023年底前保持可控。然而,建议在不久的将来准备好必要的医疗资源,以应对可能出现的新冠疫情紧急情况,特别是在2023年9月至10月期间。